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Abstract
Background: Mesenchymal stem cell therapy for osteoarthritis (OA) has been widely investigated, but the
mechanisms are still unclear. Exosomes that serve as carriers of genetic information have been implicated in
many diseases and are known to participate in many physiological processes. Here, we investigate the therapeutic
potential of exosomes from human embryonic stem cell-induced mesenchymal stem cells (ESC-MSCs) in alleviating
osteoarthritis (OA).
Methods: Exosomes were harvested from conditioned culture media of ESC-MSCs by a sequential centrifugation
process. Primary mouse chondrocytes treated with interleukin 1 beta (IL-1β) were used as an in vitro model to
evaluate the effects of the conditioned medium with or without exosomes and titrated doses of isolated exosomes
for 48 hours, prior to immunocytochemistry or western blot analysis. Destabilization of the medial meniscus (DMM)
surgery was performed on the knee joints of C57BL/6 J mice as an OA model. This was followed by intra-articular
injection of either ESC-MSCs or their exosomes. Cartilage destruction and matrix degradation were evaluated with
histological staining and OARSI scores at the post-surgery 8 weeks.
Results: We found that intra-articular injection of ESC-MSCs alleviated cartilage destruction and matrix degradation
in the DMM model. Further in vitro studies illustrated that this effect was exerted through ESC-MSC-derived
exosomes. These exosomes maintained the chondrocyte phenotype by increasing collagen type II synthesis and
decreasing ADAMTS5 expression in the presence of IL-1β. Immunocytochemistry revealed colocalization of the
exosomes and collagen type II-positive chondrocytes. Subsequent intra-articular injection of exosomes derived
from ESC-MSCs successfully impeded cartilage destruction in the DMM model.
Conclusions: The exosomes from ESC-MSCs exert a beneficial therapeutic effect on OA by balancing the synthesis
and degradation of chondrocyte extracellular matrix (ECM), which in turn provides a new target for OA drug and
drug-delivery system development.
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Background
Osteoarthritis (OA) is a common joint disease world-
wide, which exerts a significant detrimental effect on the
patients’ life quality [1]. Pharmaceutical agents, particu-
larly nonsteroidal anti-inflammatory drugs (NSAIDs)
and paracetamol, have been widely applied in the clinic.
However, their effects are largely limited to pain control
with negligible effects on cartilage maintenance, which
would ultimately lead to cartilage destruction [2, 3]. Al-
though surgical interventions such as total knee or hip
arthroplasty could partially overcome pain and deformity
in end-stage OA patients, this could also cause further
complications such as increased risks of infection,
thrombus formation and secondary surgery, particularly
in elderly patients [4–6]. Hence, there is a dire need to
develop new strategies to protect cartilage and attenuate
OA development, particularly minimally invasive inter-
ventions at the early stages of OA.
Cell transplantation is an emerging therapeutic modal-
ity for OA treatment, and mainly involves the utilization
of autologous chondrocytes and mesenchymal stem cells
[7, 8]. Although autologous chondrocytes as the main
cell type in cartilage may provide a safe and efficacious
solution, these have the inherent drawbacks of limited
availability, de-differentiation and function loss during
the process of in vitro expansion [8]. Therefore, the
application of mesenchymal stem cells (MSCs) for OA
therapy has attracted much more attention from scien-
tific investigators [7, 9–11]. Clinical applications of adult
MSCs are limited by donor source and individual phys-
ical conditions [12–14]. MSCs derived from pluripotent
embryonic stem cells (ESC-MSCs) have become another
potential and promising source of MSCs. The unlimited
self-renewal capacity and pluripotency of ESCs [15] in
turn ensures less inter-batch variability and a more
consistent supply of ESC-MSCs. Furthermore, as a cell
source for the treatment of various diseases, ESC-MSCs
have also been reported to possess immunomodulatory
properties, as well as regenerative potential, similar to
adult MSCs [16]. However, there have not yet been any
studies that have investigated their therapeutic effects
on OA and probed the underlying mechanisms involved.
Besides the well-documented immunomodulatory prop-
erties and multidifferentiation capacity of MSCs [16–18],
the communication and interaction between MSCs and
chondrocytes, either by direct cell-cell contact or indir-
ectly via secretions such as exosomes, have aroused
much interest [11, 19–22].
As one of the major pathways of extracellular signal-
ing, exosomes have been implicated in many diseases
and participate in many physiological processes. These
are derived from fusion in cell to cell communication,
as well as serve as carriers of genetic information [23].
Recently, exosomes derived from MSCs have received
much attention due to a study showing that severe
graft versus host disease (GVHD) can be treated with
MSCs-derived extracellular vesicles [24], thus sug-
gesting that the observed therapeutic effects of MSCs
can in fact be reproduced by MSCs-derived exosome
treatment [19, 25].
In this study, we report the positive therapeutic effects
of ESC-MSCs on osteoarthritis, and investigate the
underlying mechanisms involved.
Methods
Mice and OA model
Thirty-two 2-month-old C57BL/6 J mice purchased
from the animal center of Zhejiang University were uti-
lized for all experiments. The mice were anesthetized
with sodium pentobarbital (8 mg/ml, 1 ml/100 g) and
randomly distributed into experimental and control
groups. Among them, 12 mice were in the sham group,
and 20 mice were utilized for the experimental OA
model, which was induced by destabilization of the med-
ial meniscus (DMM) surgery, following the transection
of the medial meniscotibial ligament as previously de-
scribed [26]. In the first animal section, DMM surgery
was performed in the bilateral knee joints and five mice
were allocated to each group. Three mice were allocated
to each sham group. OA pathology developed gradually
throughout 4 weeks before single intra-articular injec-
tion of 5 μL ESC-MSCs (1 × 106/joint) or 5 μL PBS per
joint with a microliter syringe (Hamilton Company,
Reno, NV, USA, 1702) and 5 mm 30-gauge needles
(Hamilton Company, 7803-05). In the second animal
section, DMM surgery was performed in the bilateral
knee joints and five mice were allocated to each group.
Three mice were allocated to each sham group. OA
pathology developed gradually throughout 4 weeks be-
fore multiple injections of 5 μL exosomes isolated from
ESC-MSCs per joint or 5 μL PBS per joint, which was
performed every 3 days for 4 weeks with a microliter
syringe (Hamilton Company, 1702) and 5 mm 30-gauge
needles (Hamilton Company, 7803-05).
Cell culture
MSCs were derived from the male H1 human ES cell
line (ESC) that was obtained from WiCell Corporation.
Madison, WI, USA (http://www.wicell.org), which was
maintained in the undifferentiated state by culture in a
feeder-free system. ESC-MSCs were obtained as de-
scribed in our previous study [27]. Briefly, ESCs were
detached from Matrigel (BD, Franklin Lakes, NJ, USA,
Cat. #354234) coated plates by a 10-minute (min) incu-
bation with 0.02% (w/v) EDTA (Sigma-Aldrich, St. Louis,
MO, USA, Cat. #E8008) and seeded onto a gelatinized
10-cm plates. The cells were cultured in L-DMEM (Life
Technologies, Carlsbad, CA, USA, Cat. #11885084)
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supplemented with 10% (v/v) fetal bovine serum (FBS;
Life Technologies, Cat. #10099-141). The cells were
then trypsinized (0.05% (w/v), Life Technologies, Cat.
#15400-054) upon reaching 80% confluency and then
plated at a density of 103 cells/cm2. The medium was
pre-processed to delete the suspension in FBS with cen-
trifugation at 110,000 × g overnight at 4 °C, according
to the published protocol of Thery et al. [28]. Cells be-
tween passage number 4 and 7 were utilized.
Chondrocyte isolation and culture
Primary chondrocytes were obtained from nine C57BL/6
mice within 2 days after birth. The articular cartilage de-
rived from the terminal of tibia and femur was digested
with 0.2% (w/v) type II collagenase [29, 30], then ex-
panded in medium containing F12 (Life Technologies,
Cat. #88215) with 10% (w/v) FBS (Life Technologies,
Cat. #10099-141), and 1% (w/v) penicillin/streptomycin
(Life Technologies, Cat. #15140-122). Chondrocytes at
the first passage were seeded into 24-well plates contain-
ing glass slides for immunofluorescence analysis and six-
well plates for western blot analysis. At 24 hours after
cell seeding, we changed the medium into that with or
without 2 ng/mL interleukin 1 beta (IL-1β) (PeproTech,
Rocky Hill, NJ, USA) according to the experimental
design. Forty-eight hours later, the cells were collected
for analysis. Cells within 3 passages were utilized.
Colony-forming unit assay
ESC-MSCs were seeded at approximately 20 cells/cm2 in
triplicates and cultured for up to 21 days with regular
medium replenishment every 3–4 days. The colonies
were stained with 1% (w/v) crystal violet (Sigma-Aldrich,
Cat. #3886) in methanol for 10 min.
Flow cytometry
Cells were harvested by trypsinization (0.05% (w/v); Life
Technologies, Cat. #15400-054) for 2 min, and the cell
pellet was resuspended in PBS to a titer of 106/100 μL.
The cell suspension was incubated with the following
antibodies respectively. CD34-FITC (Miltenyi Biotec,
Bergisch Gladbach, Germany, Cat. #130-098-142),
CD45-PE (Miltenyi Biotec, Cat. #130-080-201), CD73-
PE (Miltenyi Biotec, Cat. #130-112-060), CD90-FITC
(Miltenyi Biotec, Cat. #130-095-403) and CD105-FITC
(Miltenyi Biotec, Cat. #130-112-327). About 2 μL of
each antibody (1:10 diluted according to the datasheet
of the antibodies) per tube was added and incubated for
10 min in darkness at 2–8 °C. Cells were washed with
PBS completely and resuspended in 1% (w/v) parafor-
maldehyde. Samples were run on a FC500MPL flow
cytometer (Beckman Coulter, Brea, CA, USA) and the
data were analyzed by FlowJo vX.0.7 software (FlowJo
LLC, Ashland, OR, USA).
Trilineage differentiation assay
We tested the multidifferentiation potential of the ESC-
MSCs toward the osteogenic, adipogenic, and chondro-
genic lineages in vitro as previously described [31, 32].
Briefly, osteogenic differentiation of MSCs was induced
with 10% (v/v) FBS, 1 mM β-glycerol phosphate, 10-8 M
dexamethasone, and 50 μg/mL ascorbic acid. Adipogenic
differentiation was induced with 10% (v/v) FBS, 500 μM
1-methyl-3-isobutylxanthine, 10-9 M dexamethasone,
and 60 μM indomethacin. Chondrogenic differentiation
was induced in micromass culture in the presence of
10 ng/mL TGF-β3 (PeproTech), 50 μg/mL ascorbic acid,
1% (v/v) insulin, transferrin, and selenium solution (Life
Technologies, Cat. #41400045), 10-7 M dexamethasone,
100 μM sodium pyruvate (Gibco, Cat. #11360070). In-
duction to these lineages was stopped after 3 weeks and
then assessed by Alizarin red staining, oil red staining,
and Safranin O staining respectively.
Isolation of exosomes from ESC-MSCs medium
The exosomes were isolated from 600 mL of ESC-MSCs
culture medium, which were collected when cells have
attained around 60% confluency, and were finally re-
suspended in 600 μL PBS. The isolation and purification
followed the multistep ultracentrifugation process as
previously described [28]. Briefly, the conditioned
medium containing exosomes (CM + Exo) was obtained
by centrifugation at 2000 × g for 10 min at 4 °C to re-
move dead cells and 10,000 × g for 30 min at 4 °C to re-
move cell debris. This was followed by centrifugation at
110,000 × g for 90 min at 4 °C to separate the exosomes
from the CM + Exo. At the same time, the CM without
exosomes (CM-Exo) was also collected. The exosomes
were washed with PBS and subjected to a final centrifu-
gation, prior to being stored in PBS at -80 °C.
For tracking, 100 μL of exosomes were transferred to a
1.5 mL tube, and were incubated with 10 μM DiI (Beyo-
time, Shanghai, China, Cat. #C1036) at 37 °C for 15 min,
washed with PBS at 110,000 × g for 90 min at 4 °C, and
then stored in 100 μL PBS at -80 °C.
Western blot assay
Cellular protein was extracted with RIPA lysis buffer
(Solarbio, Beijing, China, Cat. #R0010), and the total
protein concentration was determined with a BCA Pro-
tein Assay Kit (Pierce, Rockford, IL, USA, Cat. #23225).
The 20 μg extracted cellular protein was loaded on 10%
(w/v) SDS-PAGE-denaturing gels. After electrophoresis,
the proteins were transferred to a polyvinylidene
difluoride membrane and blocked in 5% (w/v) bovine
serum albumin (BSA, Sangon Biotech, Shanghai, China,
Cat. #9048-4b-8) for 1 h at room temperature. The
membrane was incubated overnight at 4 °C with mouse
anti-collagen type II (Col II) (1:500; COL2A1, Santa
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Cruz Biotechnology, Dallas, TX, USA, Cat. #sc-52658),
rabbit anti-ADAMTS5 (1:250; Abcam, Cambridge, MA,
USA, Cat. #ab41037) or mouse anti-GAPDH (1:1000;
Beyotime, Cat. #AG019) antibody. After washing in Tris-
buffered saline with Tween-20 (TBST), the horseradish
peroxidase (HRP) secondary antibodies: HRP-labeled goat
anti-mouse IgG (1:1000; Beyotime, Cat. #A0216) and goat
anti-rabbit IgG antibody, peroxidase-conjugated (1:1000;
EMD Millipore, Billerica, MA, USA, Cat. #AP132P) was
diluted in 5% (w/v) BSA solution and incubated accord-
ingly with the membrane for 1 h at room temperature
(RT). The excessive secondary antibody was washed off by
TBST, and a chemiluminescent signal was generated by
the ECL Imaging Kit (Thermo Fisher Scientific, Waltham,
MA, USA, Cat. #32209).
Exosomes (1:1000) and supernatant of ESC-MSCs
were suspended in sample loading buffer solution (with-
out 2-mercaptoethanol). Protein concentration was de-
termined by Micro BCA™ Protein Assay Kit (Pierce, Cat.
#23235). Equal volume of protein samples (40 μL) were
loaded on 12% (w/v) SDS-PAGE-denaturing gels. After
electrophoresis, protein was transferred to a polyvinyli-
dene difluoride membrane and blocked in 5% bovine
serum albumin (BSA, Sangon Biotech, Cat. #9048-4b-8)
for 1 h at RT. The membrane was incubated overnight
at 4 °C with rabbit anti-CD9 (1:2000; Abcam, Cat.
#ab92726) or mouse anti-CD63 (1:200; Santa Cruz Bio-
technology, Cat. #sc-31211) antibody. After washing in
Tris-buffered saline with Tween-20(TBST), the horse-
radish peroxidase (HRP) secondary antibodies such as
peroxidase-conjugated goat anti-rabbit IgG antibody
(1:1000; EMD Millipore, Cat. #AP132P) and HRP-
conjugated donkey anti-goat IgG antibody (1:1000; R&D
Systems, Minneapolis, MI, USA, Cat. #HAF109) were di-
luted in 5% BSA solution and incubated accordingly with
the membrane for 1 h at RT. The excessive secondary
antibody was washed off by TBST, and a chemilumines-
cent signal was generated by ECL imaging kit (FDbio-
Femto ECL, Belfort, France, Cat. #FD8030).
Immunocytochemistry
The chondrocytes were fixed in 4% (w/v) buffered para-
formaldehyde solution for 15 min, followed by
permeabilization with 0.2% (w/v) Triton X-100 for 10 min.
The fixed cells were then incubated with primary anti-
bodies: mouse anti-Col II antibody (1:100; EMD Millipore,
Cat. #MAB8887) and rabbit anti-ADAMTS5 (1:100;
Abcam, Cat. #ab41037) at 4 °C overnight and were washed
with PBS thoroughly. Subsequently, these cells were incu-
bated with the corresponding goat anti-mouse IgG (H + L)
cross-adsorbed secondary antibody, Alexa Fluor 488 (1:250;
Invitrogen, Carlsbad, CA, USA, Cat. #A11001) and F(ab’)2-
goat anti-rabbit IgG(H+ L) cross-adsorbed secondary anti-
body, Alexa Fluor 555 (1:250; Invitrogen; Cat. #21430),
respectively. Finally, the cell nuclei were counterstained by
DAPI (1:5000; Beyotime; Cat. #C1002) and imaged under
confocal microscopy (Olympus, Tokyo, Japan, BX61W1-
FV1000). The DAPI-positive cells were counted as the total
cell number (X), while the cells stained with green fluores-
cence were counted as the Col II-positive cell number (Y).
The Col II-positive cell percentage = Y/X*100%. Three in-
dependent staining tests were performed. Five visual fields
were randomly selected from each sample and the cells
were counted by a technician in a single blinded manner.
The immunofluorescence intensity of ADAMTS5 was
quantified by the ImageJ software (ImageJ v2.1.4.7, National
Institutes of Health, Bethesda, MD, USA).
Tissue histology and immunohistochemistry
Mouse joints were isolated and fixed in 4% buffered
paraformaldehyde for 24 h, then decalcified in 10% (w/v)
EDTA (pH 7.4) for 21 days (d) at 4 °C before being em-
bedded in paraffin. Sagittal joint sections at 6 μm thick-
ness were processed for Safranin O and Fast Green
staining. Cartilage destruction was evaluated using the
Osteoarthritis Research Society International (OARSI)
scoring system according to the percentage of the verti-
cal clefts/erosion to the calcified cartilage [26]. All four
parts of the joint: medial femoral condyle, lateral femoral
condyle, medial tibial plateau and lateral tibial plateau
presented in the figures were semi-quantitatively scored
according to the recommended OA grading table
(Table 1) supplied by Glasson et al. The OA grading of
each joint is expressed as the maximum or summed
score of the four quadrants, respectively. Immunohisto-
chemical staining was performed using a standard proto-
col. After dewaxing, heat-induced antigen retrieval was
performed in retrieval solution overnight at 64 °C. The
solution was composed of 0.1 M trisodium citrate
(20.5 mL) and 0.1 M citric acid anhydrous (4.5 mL) in
225 mL distilled water. Sections were incubated over-
night at 4 °C with primary antibodies: rabbit anti-
ADAMTS5 (1:100; Abcam; Cat. #ab41037), mouse anti-
Col II (1:50; COL2A1, Santa Cruz Biotechnology, Cat.
#sc-52658), rabbit anti-aggrecan neoepitope antibody
(1:100; Novus Biologicals, Littleton, CO, USA, Cat.
#NB100-74350SS). After washing off excess primary
antibodies, these samples were incubated with second-
ary antibodies conjugated with HRP: HRP-labeled goat
anti-mouse IgG (1:200; Beyotime, Cat. #A0216) and
goat anti-rabbit IgG antibody, peroxidase-conjugated
(1:600; EMD Millipore, Cat. #AP132P) was diluted in
1% (w/v) BSA solution and incubated the section for
1 h at room temperature (RT). DAB detection system
(Solarbio, Cat. #DA1010) were used to visualized the
section. The stained specimens were photographed
digitally under a slide scanning machine (Pannoramic
MIDI, 3DHISTECH Ltd., Budapest, Hungary).
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Transmission electron microscopy
Purified exosomes were fixed with 1% (w/v) glutaralde-
hyde in PBS (pH 7.4). After rinsing, a 20 μL drop of the
suspension was loaded onto a formvar/carbon-coated
grid, negatively stained with 3% (w/v) aqueous phospho-
tungstic acid for 1 min, and then imaged under trans-
mission electron microscopy (HT7700, Hitachi, Tokyo,
Japan). The diameter of the exosome was evaluated by
the ImageJ software (ImageJ v2.1.4.7, National Institutes
of Health), and we analyzed the diameter distribution
and percentage values with the Excel software (Microsoft
(Redmond, WA, USA) Excel for Mac version15.24).
Quantitative real-time polymerase chain reaction
(qRT-PCR)
Total RNA was isolated from mouse primary chondro-
cytes by lysis in TRIzol (Takara, Shigo, Japan, Cat.
#9109). The reverse transcription process applied Rever-
Tra Ace qPCR RT Master Mix (Toyobo, Osaka, Japan,
Cat. #FSQ-201). The qRT-PCR was performed utilizing
Brilliant SYBR Green QPCR Master Mix (Takara, Cat. #
RR420A) with a LightCycler apparatus (480II, Roche,
Mannheim, Germany). The amplification efficiencies of
primer pairs were validated to enable quantitative com-
parison of gene expression. All primer sequences (Invi-
trogen) were designed using Primer 5.0 software (see
Additional file 1). Each qRT-PCR was performed three
times on at least three different experimental replicates,
and results were normalized to those obtained with the
endogenous reference gene (Gapdh).
Statistical analysis
All data were expressed as mean ± SE unless otherwise
stated. All experiments in vitro were repeated independ-
ently at least twice in addition to the triplicates applied
in each experiment. Statistical results were analyzed and
bar charts were constructed with GraphPad Prism ver-
sion 5.0 (GraphPad Software, San Diego, CA, USA).
Statistical results were considered significant when the p
value was less than 0.05. Two-tailed Student’s t test was
used to compare two groups at the same time point.
One-way ANOVA including the Tukey-Kramer post hoc
test was used to compare multiple groups at the same
time point. Experimental data of the in vivo experiment
was analyzed by the Mann-Whitney test with the SPSS
software (IBM Corp., Armonk, NY, USA).
Results
Establishment of ESC-MSCs
The human ESC is a cell line obtained from WiCell Cor-
poration. The ESCs cultured on Matrigel yielded com-
pact colonies with sharp borders (Fig. 1a). These cells,
however, adopted a fibroblast-like morphology upon
plastic adhesion. Compared with ESCs, these cells dis-
played spindle-shaped morphology in monolayer culture
and were distributed sparsely (Fig. 1a). When these cells
were seeded at densities as low as 200 cells per 9.5 cm2
well, they developed into round and tight colonies
(Fig. 1b). Flow cytometry analysis showed that more
than 95% of these cells expressed the classical MSC
markers including CD73, CD90, and CD105, while no
cells expressed hematopoietic markers such as CD34
and CD45 (Fig. 1c). Upon osteogenic inducement, these
cells synthesized matrix which were stained dark brown
by Alizarin red, indicating calcium deposition. After adi-
pogenic induction, these cells displayed round orange
droplets within the cytoplasm upon oil red staining,
which indicates formation of oil droplets. The cells were
kept in aggregates before chondrogenic differentiation,
resulting in formation of a pellet and synthesized matrix
which were stained orange and red by Safranin O stain-
ing, thus indicating cartilage matrix formation (Fig. 1d).
Alleviation of osteoarthritis by ESC-MSCs
To evaluate the therapeutic effects of ESC-MSCs on
osteoarthritis, we injected 5 μL of cell suspension
(1 × 106) directly in the bilateral joints of five OA
mice at 4 weeks after DMM surgery as the ESC-MSC
group and injected 5 μL of PBS in the bilateral joints
of five OA mice at 4 weeks after DMM surgery as the
control group. We harvested the joint samples after
the following 4 weeks (Fig. 2a). Histological evaluation
Table 1 The OA Grading Table
Scores Osteoarthritis damage
0 Normal
0.5 Loss of Safranin O without structural changes
1 Small fibrillations without loss of cartilage
2 Vertical clefts down to the layer immediately below the superficial layer and some loss of surface lamina
3 Vertical clefts/erosion to the calcified cartilage extending to <25% of the articular surface
4 Vertical clefts/erosion to the calcified cartilage extending to 25–50% of the articular surface
5 Vertical clefts/erosion to the calcified cartilage extending to 50–75% of the articular surface
6 Vertical clefts/erosion to the calcified cartilage extending >75% of the articular surface
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revealed that the PBS-injected DMM mice have
more sever fibrillation and erosion of the calcified
cartilage. The maximal OARSI score was 3.8 ± 1.04,
and the summed OARSI score was 10.8 ± 3.37. How-
ever, the ESC-MSC-injected DMM mice exhibited
less fibrillation with vertical clefts only down to the
layer immediately below the superficial layer, and
some loss of surface lamina. The maximal OARSI
score was 2.6 ± 0.45, and the summed OARSI score
was 7.6 ± 1.97 (Fig. 2b). Hence, the OARSI evalu-
ation in the ESC-MSCs group revealed significantly
lower maximal and summed scores than the control
group (p = 0.011 and 0.044 respectively) (Fig. 2c) (see
Additional files 2 and 3). The immunohistochemistry
results showed that the cartilage of the ESC-MSCs
group exhibited much stronger Col II-specific staining,
much weaker ADAMTS5-specific staining and aggrecan
neoepitope-specific staining than the control group
(Fig. 2d) (see Additional file 2).
Effect of ESC-MSCs culture medium deficient in exosomes
on cartilage matrix maintenance
To investigate whether exosomes or cytokines exert a
critical effect on the alleviation of OA by ESC-MSCs, we
harvested the conditioned medium (CM + Exo), the con-
ditioned medium without exosomes (CM-Exo) and the
exosomes from the ESC-MSCs culture medium (Fig. 3a).
Under TEM, the isolated exosomes were round lipid
bilayers-vesicles and approximately 30–200 nm in
diameter (Fig. 3b). The diameters of isolated exosomes
ranged from 38 nm to 169 nm and the mean value was
78 nm (Fig. 3c). The concentration of the isolated exo-
somes is 176.2 μg/mL (see Additional file 4). The western
blot results confirmed the identity of these isolated exo-
somes by showing thick CD63 and CD9 bands, while
there was a weak CD9 band and no CD63 band in the
supernatant of cultured medium (Fig. 3d).
Initially, we observed the effects of CM-Exo in maintain-
ing the cartilage matrix. In vitro, immunocytochemistry
Fig. 1 Establishment and identification of ESC-MSCs. a Morphology of the ESCs (left) and induced MSCs (right). Scale bars, 500 μm. b Colony
formation by ESC-MSCs. Gross view of the whole well was shown in the small image. Scale bars, 500 μm. c Surface molecular profile of the
ESC-MSCs, which were negative in CD34 and CD45 expression, but positive in CD73, CD90, and CD105 expression. The dotted lines indicate
isotype-matched mouse IgG Ab control staining. d Identification of osteogenic, chondrogenic and adipogenic cells by Alizarin red staining,
oil red staining and Safranin O staining respectively. Scale bars, 200 μm. ESC-MSCs embryonic stem cell-derived mesenchymal stem cells
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showed that IL-1β could obviously inhibit the synthesis
of Col II and increase the expression of ADAMTS5.
However, this effect could be reversed by CM + Exo but
not CM-Exo (Fig. 4a). Furthermore, the quantification
results showed that the percentage of Col II-positive
cells significantly increased from 22.08% ± 13.6% in the
IL-1β group to 57.80% ± 7.9% in the CM + Exo group
(p = 0.0068), which was similar to the control group
(55.48% ± 20.7%). By contrast, the percentage of Col II-
positive cells in the CM-Exo group was much lower at
27.27% ± 9.2%, which was similar to the IL-1β group
(Fig. 4b). The ADAMTS5 immunofluorescence inten-
sity was greatly upregulated after IL-1β treatment
(0.044 ± 0.003) compared with the control group (0.02 ±
0.007). The CM + Exo treatment can downregulate the
ADAMTS5 immunofluorescence intensity to 0.022 ±
0.004, while the CM-Exo can only downregulate the in-
tensity to 0.028 ± 0.002 (Fig. 4b). These results were
doubly confirmed by Western blot analysis (Fig. 4c).
The CM + Exo group displayed an obviously thicker
Col II band than the CM-Exo group, which was similar
to that of the control group. Meanwhile, the CM + Exo
group had an obviously lighter ADAMTS5 band than
the CM-Exo group, which was similar to that of the
control group.
Effects of exosomes derived from ESC-MSCs on cartilage
matrix maintenance
To further confirm the effects of exosomes on cartilage
matrix maintenance, the isolated exosomes were directly
added into the chondrocytes with IL-1β treatment.
Immunocytochemistry showed that the Col II expression
in the exosomes group obviously increased, while the
ADAMTS5 expression in this group obviously decreased
(Fig. 5a). The quantification results confirmed that
there were 50.18% ± 8.8% of Col II-positive cells in the
Fig. 2 Recovery of cartilage destruction by intra-articular injection of ESC-MSCs in a DMM model. a Flowchart of the in vivo experiment. b The
Safranin O and Fast Green staining of cartilage destruction at 8 weeks after surgery. Boxed regions were magnified and shown in the next line.
Scale bars, 200 μm. c OARSI scores of cartilage destruction. n = 10 in each group. d Immunohistochemical staining of COL II and ADAMTS5.
Boxed regions show the gross view. Scale bars, 100 μm. COL II collagen type II, ESC-MSCs embryonic stem cell-derived mesenchymal stem cells,
OARSI Osteoarthritis Research Society International
Wang et al. Stem Cell Research & Therapy  (2017) 8:189 Page 7 of 13
Fig. 3 Isolation and identification of exosomes. a Flowchart of conditioned medium (CM + Exo), exosomes and conditioned medium without
exosomes (CM-Exo) preparation. b Exosomes morphology. Scale bar, 500 nm. c The diameter distribution of isolated exosomes. d Expression of
CD9 and CD63 by exosomes and supernatant
Fig. 4 Effects of CM + Exo and CM-Exo on primary chondrocytes phenotype maintenance in the presence of IL-1β. a Expression of Col II (green)
and ADAMTS5 (red) by primary chondrocytes treated with CM + Exo and CM-Exo. Scale bar, 40 μm. b Percentages of the Col II-positive cells with
different treatments and immunofluorescence intensity of ADAMTS5 with different treatments. c Expression of Col II and ADAMTS5 by the primary
chondrocytes with different treatments. COL II collagen type II, IL-1β, interleukin 1 beta
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exosomes group, which was significantly higher than
that in the IL-1β group (22.08% ± 13.6%) (p = 0.0323)
(Fig. 5b). The immunofluorescence intensity of ADAMTS5
was upregulated from 0.024 ± 0.007 to 0.044 ± 0.003
after IL-1β treatment; but upon addition of exosomes,
the intensity was downregulated to 0.027 ± 0.004
(Fig. 5b). Meanwhile, gene expression showed the simi-
lar effects of exosome treatment (see Additional file 5).
Meanwhile, the DiI-labelled exosomes can be detected
within the Col II-expressing chondrocytes (Fig. 5c),
thus indicating the colocalization between exosomes
and chondrocytes. The western blot results also showed
gradually denser Col II bands and gradually fainter
ADAMTS5 bands of chondrocytes with increasing dos-
ages of exosomes. (Fig. 5d).
Alleviation of osteoarthritis by exosomes from ESC-MSCs
Finally, the effects of ESC-MSC-derived exosomes in
alleviating osteoarthritis was evaluated in the DMM
mouse model. The injection was started 4 weeks after
DMM surgery. Five microliters exosomes or 5 μL PBS
were injected into bilateral knee joints of mice in exo-
somes group and PBS group respectively, every 3 days
for 4 weeks (Fig. 6a). The SO staining results showed
that the fibrillations had extended to some degree to the
calcified cartilage in the PBS group. The maximal
OARSI score was 3.5 ± 0.76, and the summed OARSI
score was 9.4 ± 2.49. By contrast, the exosomes group
exhibited milder OA pathology such as roughened ar-
ticular surface fibrillations below the superficial layer
and some loss of lamina. The maximal OARSI score was
2.7 ± 0.66, and the summed OARSI score was 7.3 ± 1.75
(Fig. 6b) (see Additional files 2 and 6). Both the maximal
and total OARSI scores were significantly lower in the
exosomes group than the control (Fig. 6c). The immuno-
histochemistry results showed that the cartilage of the
exosomes group displayed much stronger Col II-specific
staining, much weaker ADAMTS5-specific staining and
aggrecan neoepitope-specific staining than the control
group (Fig. 6d) (please refer to Additional file 2).
Fig. 5 Direct effects of exosomes on primary chondrocyte phenotype maintenance in the presence of IL-1β. a Expression of Col II (green) and
ADAMTS5 (red) by primary chondrocytes treated with exosomes. Scale bar, 40 μm. b Percentages of the Col II-positive cells with/without the
addition of exosomes and immunofluorescence intensity of ADAMTS5 with/without the addition of exosomes. c Colocalization of exosomes (red),
Col II (green) and chondrocytes (blue nuclei). Scale bars, 10 μm. d Expression of Col II and ADAMTS5 by the primary chondrocytes upon addition
of different concentrations of exosomes. COL II collagen type II, IL-1β, interleukin 1 beta
Wang et al. Stem Cell Research & Therapy  (2017) 8:189 Page 9 of 13
Discussion
In this study, we successfully established MSCs from
the H1 human ES cell line for OA treatment. These
ESC-MSCs fulfilled the minimal criteria of MSCs as de-
fined by the International Society for Cellular Therapy
[33], which encompass the plastic adherence property,
fibroblastic morphology, molecular profile phenotype,
proliferative capacity (see Additional file 4A), and trili-
neage differentiation potential of these cells. Our re-
sults showed that intra-articular injection of ESC-MSCs
significantly impeded cartilage destruction in a DMM
OA mice model. According to the immunohistochemis-
try results, the ESC-MSCs can increase Col II (the
major cartilage matrix component) expression and de-
crease ADAMTS5 (aggrecan-degrading enzyme 5) ex-
pression in the cartilage matrix.
It is well documented that the secretome of MSCs
mediates many of the beneficial therapeutic effects of
MSCs on various diseases, and includes a diverse array
of cytokines, exosomes, and nuclei acids. Among these,
cytokines are the most well studied, but accumulating
scientific evidence suggests the important roles of other
components. In the past few years, the exosomes derived
from MSCs have been reported to have a therapeutic
role in various diseases [34, 35]. Hence, we investigated
whether the exosomes from ESC-MSCs can alleviate the
OA process. To distinguish the activity of exosomes and
other soluble components that maintain the chondrocyte
phenotype in an inflammatory environment, we har-
vested the CM + Exo (containing both exosomes and
other soluble components), CM-Exo (excluding exo-
somes) and exosomes by serial centrifugation (Fig. 3a).
Fig. 6 Recovery of cartilage destruction by intra-articular injection of exosomes from ESC-MSCs in a DMM model. a Flowchart of the in vivo
experiment. b Safranin O staining of articular cartilage. Boxed regions were magnified and shown in the next line. Scale bars, 200 μm. c OARSI
scores of cartilage destruction. n = 10 in each group. d Immunohistochemical staining of COL II and ADAMTS5. Boxed regions show the gross
view. Scale bars, 100 μm. COL II collagen type II, OARSI Osteoarthritis Research Society International
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The following results showed that the CM + Exo de-
creased ADAMTS5 expression and maintained Colla-
gen type II synthesis by primary chondrocytes under
IL-1β treatment in vitro. These effects were almost
identical to that of exosomes that play the same role in
a dose-dependent pattern. However, the CM-Exo group
exhibited lower capacity in maintaining the chondro-
cyte phenotype. This thus indicates that the exosomes
may be one of the major effectors of OA treatment
mediated by ESC-MSCs. Additionally, upon tracking
the location of exosomes, the exosomes can be found
to be colocalized with Col II-expressing chondrocytes,
suggesting that these may fuse with chondrocytes and
exert a direct effect on these cells.
To confirm the regenerative effects of exosomes in
vivo, the exosomes were directly injected into the knee
joints of the DMM-induced OA model. The results also
confirmed that the exosomes derived from ESC-MSCs
effectively prevented the progress of cartilage destruc-
tion in an OA model.
Previous studies have shown that the MSCs can be a
candidate for osteoarthritis therapy [7, 11, 36]. Most re-
search focus on adult MSCs, which may vary between
donors’ physical conditions. Here we attempted to estab-
lish MSCs from a promising and consistent new source
(ESCs). And these ESC-MSCs displayed similar charac-
teristics to adult MSCs with therapeutic potential in OA.
Recent studies have shown that paracrine mechanisms,
particularly exosomes are responsible for the therapeutic
effects of MSCs mediated OA treatment [37–39]. Tao
et al. [38] demonstrated that exosomes derived from
human synovial MSCs can promote chondrocyte prolif-
eration and migration. However, only when the exo-
somes were derived from miR-140-5p overexpressing
MSCs, could these exert a regenerative effect in OA
treatment. Zhu et al. [39] compared exosomes secreted
by induced pluripotent stem cell-derived MSCs and
synovial membrane-derived MSCs for OA treatment in
a collagenase-induced mouse model. Both studies dem-
onstrated that the exosomes from MSCs could some-
how prevent OA progression. And it appears that the
exosomes from induced pluripotent stem cell-derived
MSCs may be more efficient than the exosomes from
synovial membrane-derived MSCs for OA treatment. In
this study, we utilized ESC, which is also a pluripotent
cell line, as the source of MSCs. Consistent with the
published results, the exosomes derived from ESC-
MSCs effectively maintained chondrocyte phenotype
both in vitro and in vivo. Previously, Zhang et al. re-
ported that the exosomes from ESC-MSCs can enhance
cartilage repair in a cartilage defect model [22]. How-
ever, there is no direct evidence that has demonstrated
the regenerative effects of the exosomes from these
cells on OA. In this experiment, we used a DMM
mouse model, which is currently the preferred animal
OA model resembling the progressive OA pathology.
Different from a simple cartilage defect, OA is considered
a multifactorial cartilage lesion disease within a chronic
inflammatory microenvironment. In our model, the cartil-
age lesion was caused by accumulated damage on the cen-
tral weight-bearing area of the medial femoral condyle
and the medial tibial plateau. This model is also suffi-
ciently sensitive to allow investigation of new therapeutic
strategies that confer significant protection against OA
progression. In this model, exosomes by themselves were
demonstrated to be able to prevent lesion progression and
exert a similar regenerative effect as ESC-MSCs. Further
in vitro analysis revealed that this effect was mediated by
direct contact between exosomes and chondrocytes and
involves balancing the synthesis of extracellular matrix
protein Collagen type II with expression of the matrix
degradation enzyme ADAMTS5.
Although this study showed that ESC-MSC-derived
exosomes play a significant role in preventing OA
progression similar to ESC-MSCs, there are still some
limitations of our results. We set the two animal exper-
iments sequentially not simultaneously. Meanwhile, the
frequency of injection was also different between the
ESC-MSC and exosomes groups. Hence, we cannot
compare the therapeutic efficacy of exosomes with
ESC-MSCs directly, as we cannot exclude other factors
that may work together with exosomes to facilitate
ESC-MSC-mediated OA treatment. In addition, we only
set a single time point and a single dosage in the animal
experiment. It would be more clinically relevant to add
more time points of intervention in our experiments to
explore whether there is a therapeutic window in OA
disease. Furthermore, the effective dosage of exosomes
needs to be optimized. To date, the active ingredients
in exosomes are unknown. As the exosome is a complex
carrier which contains lipids, DNA, mRNA, miRNA,
LncRNA, and even various proteins, they exhibit thera-
peutic function through immunomodulation, bioener-
getics or biochemical effects in different disease models
[19, 21, 24, 34]. Hence, the underlying mechanisms of
their therapeutic effects on osteoarthritis need to be fur-
ther investigated in more detail.
In conclusion, the exosomes are one of the effectors
produced by ESC-MSCs to alleviate OA by balancing
the synthesis and degradation of cartilage matrix. The
study of exosomes in OA therapy has just begun, and
our results suggest that exosomes from ESC-MSCs have
great potential for OA treatment, which merits further
investigation.
Conclusions
In this study, we confirmed that ESC-MSCs can alleviate
OA in a DMM mouse model. The following in vitro
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study shows that the effects of ESC-MSCs may be
dependent on the exosomes in the CM + Exo of ESC-
MSCs. We also provided evidence that exosomes can
modulate chondrocytes to maintain Col II expression
and decrease ADAMTS5 expression under IL-1β treat-
ment. The in vivo study also confirmed the function of
exosomes on osteoarthritis treatment in an inflamma-
tory microenvironment. In summary, the exosomes
from ESC-MSCs exert a beneficial therapeutic effect on
OA by balancing the synthesis and degradation of
chondrocyte extracellular matrix (ECM), which in turn
provides a new target for OA drug and drug-delivery
system development.
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